DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...

BofA Securities maintained a Buy rating on DexCom (NASDAQ:DXCM) shares, with a steady price target of $90.00. The firm's analysts suggest the current market movement presents an appealing opportunity ...

Retirement Systems of Alabama lowered its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 2.5% in the 4th quarter, ...

在2024年，该公司在美国发布了最新版本的G系列——G7。DexCom在7月底发布第二财季业绩后，股价大幅下跌，但从长期表现来看，这一下跌并不算异常。考虑DexCom从2005年到2018年的表现可以看出。DexCom的股价曾多次大幅下跌，但其中一个 ...

and share price spikes are harder to achieve. It is not Dexcom's fault that the market bought into the CGM story and sent shares spiking >$150 – valuing the company at >$50bn – more than three ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

DexCom develops continuous glucose monitoring (CGM ... citing progress in U.S. sales and upcoming catalysts. The price target was raised to $104 from $98. Instead, as long-term investors know ...

Redburn Atlantic upgraded DexCom (DXCM) to Buy from Neutral with a price target of $115, up from $85. The company is positioned to benefit from ...

DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM ... It is, after all, trading at a much lower price-to-earnings multiple than what it has historically ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from ...